

March 2, 2016

ContraFect

MOLECULAR TREATMENTS
FOR INFECTIOUS DISEASE



ContraFect to Present at Two Upcoming Investor Conferences

YONKERS, NY -- (Marketwired) -- 03/02/16 -- [ContraFect Corporation](#) (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present at two upcoming investor conferences: the Cowen and Company 36th Annual Health Care Conference in Boston and the 28th Annual ROTH Conference in Laguna Nigel, CA.

Ms. Gregory will provide a corporate overview at the Cowen Conference at 10:40 am ET on March 9, 2016 and at the ROTH Conference at 11:30 am PT (2:30 pm ET) on March 15, 2016. Ms. Gregory will discuss ContraFect's lead programs, which include CF-301, the Company's novel approach to the treatment of *Staphylococcus aureus* (*Staph aureus*) bloodstream infections, including MRSA. CF-301 is the first and only bacteriophage-derived lysin to enter clinical development in the U.S. Ms. Gregory will also discuss CF-404, an antibody cocktail treatment for life-threatening influenza infections, covering seasonal and pandemic strains of influenza.

The presentations will be available as a webcast for a limited time. To access via the Company's website, please go to www.contrafect.com. To access the webcast directly, please use the following URLs:

Cowen and Company 36th Annual Health Care Conference

<http://wsw.com/webcast/cowen30/cont>

28th Annual ROTH Conference

<http://wsw.com/webcast/roth30/cfrx>

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening

infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant *Staph aureus* bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Examples of forward-looking statements include statements made regarding ContraFect's novel treatments for life-threatening, drug resistant infectious diseases, including protein and antibody therapeutics. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Paul Boni
ContraFect Corporation
Tel: 914-207-2300
Email: pboni@contrafect.com

Source: ContraFect Corporation